Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) represented a move of 3.09 percent or $-0.08 per share and closed its previous day trading session at $2. 1.25 Million Shares were traded in the last trading session with an Average Volume of 1.99 Million Shares. The stock currently has a Market Capitalization of 389.8 Million.
Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera’s proprietary drug candidates are designed to modulate Toll-like Receptors, the body’s first line of immune defense. Idera’s pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.
The stock traded between $1.32 and $2.87 over 1-Year time period showing its price to sales ratio of 24.36. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-3.32 and 200-Day Simple Moving Average of $1.48. Its Price to Free Cash Flow is 0 and Price to Book of 4.88.
Analyst’s recommended the stock as 1.6 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) reported its Actual EPS of $-0.1/share. The analysts offering Earnings Estimates for the company were believing that Idera Pharmaceuticals, Inc. could bring EPS of $-0.12/share. The difference between Actual EPS and Estimated EPS was 0.02 Percent. Thus showing an Earnings Surprise of 16.7 Percent.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)
In the last trading session, Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) added its value by -1.2% closing at the price of $0.31. The stock currently has market capitalization of 18.64 Million, with average volume of 3.15 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) is showing beta of -0.21. This particular value of beta suggests that Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) has historically moved -21% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) is at $-0.59.
The stock currently has RSI of 28.67. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York.
Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) topped its 52-week high price of $2.180 on 01/03/18 and 52-Week Low Price of $0.280 on 02/06/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.81% and monthly volatility of 8.77% respectively.